You are here Home » Magazine Partner Log In Contact us Why us What we do Partners Products Magazine Contact us Partner Log In Magazine 0 Category - Any - Event News Scientific Publication Product - Any - XILAPLUS® TASECTAN® DUO RHINOSECTAN® GELSECTAN® TASECTAN® APROTECOL® (infant colic) UTIPRO® PLUS Therapeutic area - Any - Allergology / ent Barrier Technology Gastroenterology Pediatrics Uro-ginecology Gastroenterology News Aprotecol® launched in Spain We are pleased to announce the launch of APROTECOL®, our new product for reducing the symptoms of infant colic, in its first market, Spain. The product is distributed by FERRER. Aprotecol® is a Class IIa CE marked medical device intended for the treatment of meteorism, aerophagy and flatulent colic in infants and children. Aprotecol® has been available as drops for oral administration in Spanish pharmacies from the beginning of September. Read more Uro-ginecology Scientific Publication UTIPRO® PLUS New scientific communication on UTIPRO® PLUS Following the publication of the experimental study by Fraile B et al. “Xyloglucan, hibiscus and propolis for the prevention of urinary tract infections: results of in vitro studies.” on Future Microbiology 2017; 12: 721-73, the authors presented a new communication at the VII International Congress of Histology and Tissue Engineering. Santiago de Compostela 5-8 Sept 2017. The results confirm the non-pharmacological barrier effect of xyloglucan and its utility in the prevention of urinary tract infections. Read more Allergology / ent Scientific Publication RHINOSECTAN® New scientific publication on Rhinosectan® A new publication carried out in a nasal mucosa model demonstrates the barrier effect of Rhinosectan®, which confirms its utility in nasal respiratory diseases such as allergic rhinitis. Rhinosectan® is a Class I medical device and complies with the Essential Requirements of Directive 93/42/EEC and subsequent amendments. (CE, Noventure SL) De Servi B et al. Protective barrier properties of Rhinosectan® spray (containing xyloglucan) on an organotypic 3D airway tissue model (MucilAir): results of an in vitro study. Allergy Asthma Clin Immunol. 2017 Aug 10;13:37 Read more Pages 1 2 3 4 5 6 7 8 9 … next › last » Let's meet in.. 2017, Oct 24 CPHI Read more 2017, Oct 28 UEGWeek 2017 - The 25th United European Gastroenterology Week Read more 2017, Nov 23 PharmaVenue Palma de Mallorca Read more 2017, Nov 27 euroPLX 65 London Read more 2018, Mar 16 EAU 18 Read more 2018, May 09 ESPGHAN 51 Read more ©Noventure 2017 Tel. 34.93.205.27.18 last modified: 11-10-2017 Legal notice | Privacy Policy | Cookies Policy In accordance with article 5 of the Spanish Law RDL1/2015, the information set out in the following sections is intended for healthcare professionals. Access to this information and all use which may be made thereof or of these contents is exclusive responsibility of those who use them. Noventure will not be held liable for any illegal or improper use or for the manipulation of the contents and information included in these pages. I am a healthcare professional I'm not a healthcare professional